Blood Cancer Journal Contents: 31 Mar 2022

The latest content from Blood Cancer Journal: 31 March 2022

Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication Yu-Jia Huo, Peng-Peng Xu [...] Wei-Li Zhao Correspondence | 29 March 2022 | Article number: 48 |  doi: 10.1038/s41408-022-00644-2

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update Abdul Hamid Bazarbachi, Rama Al Hamed [...] Mohamad Mohty Review Article | 28 March 2022 | Article number: 47 |  doi: 10.1038/s41408-022-00645-1

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis Shebli Atrash, Evelyn M. Flahavan [...] Sikander Ailawadhi Article | 23 March 2022 | Article number: 46 |  doi: 10.1038/s41408-022-00638-0

Extramedullary disease in multiple myeloma: a systematic literature review Joan Bladé, Meral Beksac [...] Paul Richardson Review Article | 21 March 2022 | Article number: 45 |  doi: 10.1038/s41408-022-00643-3

Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases Naseema Gangat, Yamna Jadoon [...] Ayalew Tefferi Article | 17 March 2022 | Article number: 44 |  doi: 10.1038/s41408-022-00639-z

Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets Ti'ara L. Griffen, Fieke W. Hoff [...] Steven M. Kornblau Article | 17 March 2022 | Article number: 43 |  doi: 10.1038/s41408-022-00623-7

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands Mirian Brink, Monique C. Minnema [...] Avinash G. Dinmohamed Correspondence | 15 March 2022 | Article number: 41 |  doi: 10.1038/s41408-022-00640-6

Clonal hematopoiesis in primary immune thrombocytopenia Yanming Wang, Tianshu Yu [...] Ming Hou Correspondence | 15 March 2022 | Article number: 40 |  doi: 10.1038/s41408-022-00641-5

Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 Müjde Durmaz, Otto Visser [...] Avinash G. Dinmohamed Article | 09 March 2022 | Article number: 38 |  doi: 10.1038/s41408-022-00637-1

secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics Harish Kumar, Suman Mazumder [...] Amit Kumar Mitra Article | 09 March 2022 | Article number: 39 |  doi: 10.1038/s41408-022-00636-2

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms Mengshi Hu, Tao Yang [...] Lijuan Chen Article | 07 March 2022 | Article number: 37 |  doi: 10.1038/s41408-022-00628-2

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma Myra Langendonk, Mathilde R. W. de Jong [...] Tom van Meerten Article | 07 March 2022 | Article number: 36 |  doi: 10.1038/s41408-022-00631-7

CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma Wen Lei, Qian Ye [...] Wenbin Qian Article | 28 February 2022 | Article number: 35 |  doi: 10.1038/s41408-022-00634-4

Journal Info Submit Manuscript RSS Feed

This email has been sent to ignoble.experiment@arconati.us by Blood Cancer Journal.

Unsubscribe Manage Alerts Privacy policy Contact us

Springer Nature Limited is a company registered in England and Wales under Company Number 785998 with its registered office at The Campus, 4 Crinan Street, London, N1 9XW, United Kingdom

Nature is part of Springer Nature. © 2022 Springer Nature Limited. All rights reserved.